Phase 4 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who have given written consent to participate
- People with heart failure that causes symptoms, rated as moderate (a classification doctors use called NYHA Class II or III)
- People who have a type of irregular heartbeat called atrial fibrillation (either coming and going, or ongoing), first diagnosed less than 24 months ago, and confirmed by at least one heart tracing test (ECG)
- People whose heart pumping strength (measured as a percentage called ejection fraction) is between 40–49%, OR is 50% or above with certain ultrasound findings showing the heart is enlarged or has thickened walls (confirm specific measurements with trial site)
- People who have either been hospitalised for heart failure in the last 6 months with certain elevated blood protein levels, OR who have certain elevated blood protein levels shown at the screening visit (confirm specific values with trial site)
Who may not be able to join:
- People who are unable or unwilling to give informed consent
- People whose atrial fibrillation is not suitable for treatment aimed at restoring normal heart rhythm
- People who have previously had a catheter ablation procedure or surgery on the upper chambers of the heart to treat atrial fibrillation
- People whose heart failure is severely unstable at the time of enrolment (though enrolment may be considered after stabilisation)
- People who need a heart valve procedure or surgery within the next 3 months
- People who have heart surgery planned within the next 3 months
- People who have previously had a heart transplant, are listed for one, or are listed for a heart-assist device
- People with an untreated thyroid condition (though enrolment may be considered after successful treatment)
- People who cannot safely take blood-thinning medication by mouth
- People with any illness that is expected to limit life expectancy to less than one year
- People with an active infection throughout the body (though enrolment may be considered after successful treatment)
- People who are currently pregnant or breastfeeding, or people of childbearing potential who are not using a highly effective form of contraception
- People who are already participating in another clinical trial
- People who would be unable to follow the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Abdul Parwani, Dr., Head of Electrophysiology; Charité University Medicine Berlin, CVK
Phone: +4930450565383
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary outcome is defined as a composite of cardiovascular death, stroke and total (first and recurrent) unplanned cardiovascular hospitalization for heart failure or acute coronary syndrome.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.